King & Spalding advises pharmaceutical, biotechnology and medical technology clients at all stages of their development and in connection with a wide variety of strategic corporate transactions. King & Spalding’s work for pharmaceutical, biotechnology and medical technology companies includes mergers and acquisitions, joint ventures, strategic alliances, research and development agreements, co-promotion agreements and licenses. These transactions involve expertise across various teams, from corporate to intellectual property. Our clients in such matters range from privately held, venture-backed companies to large public companies.
Client benefits:
The integration of our corporate practice with the services provided to our clients by our significant intellectual property practice group provides many benefits to our corporate pharmaceutical, biotechnology and medical technology clients:
- Thorough knowledge of the pharmaceutical, biotechnology and medical technology industry
- Providing thought leadership on product ownership, acquisition, development and promotion
- Understanding of market leading structures for licensing, joint ventures and other collaborative arrangements
- Providing coordinated assistance in finance and M&A transactions
- Proactive advice on business and legal developments affecting the pharmaceutical, biotechnology and medical technology industry
Recognitions:
- Ranked tenth (tie) by Mergermarket among law firms by deal volume in 2006 for U.S. based biotechnology M&A transactions
- Board representation on the Georgia Biomedical Partnership, a statewide non-profit organization whose mission is to foster a social, political, economic and educational environment in which pharmaceutical, biotechnology and medical technology companies can succeed
- Ranked among the top 20 firms for first quarter 2007 M&A transactions in each of Canada, Latin America and the United States by Thomson Financial
